Sage Therapeutics (SAGE) Earnings Date, Estimates & Call Transcripts → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free sage Stock Alerts $12.95 +0.06 (+0.47%) (As of 04/23/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateApr. 25Before Market OpensConfirmedActual EPS (Feb. 14) -$0.55 Beat By $0.73 Consensus EPS (Feb. 14) -$1.28 Read Call TranscriptListen to Call Get Sage Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for SAGE and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueSAGE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SAGE Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. Sage Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($1.92)($1.44)($1.70)Q2 20244($2.00)($1.45)($1.70)Q3 20244($2.01)($1.42)($1.70)Q4 20244($2.05)$1.36($1.02)FY 202416($7.98)($2.95)($6.11)SAGE Earnings Date and InformationSage Therapeutics last issued its earnings data on February 14th, 2024. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.73. The company earned $77.97 million during the quarter, compared to the consensus estimate of $60.15 million. Its revenue was up 2621.5% compared to the same quarter last year. Sage Therapeutics has generated ($9.06) earnings per share over the last year (($9.06) diluted earnings per share). Earnings for Sage Therapeutics are expected to grow in the coming year, from ($6.30) to ($4.53) per share. Sage Therapeutics has confirmed that its next quarterly earnings report will be published on Thursday, April 25th, 2024. Sage Therapeutics will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call.. Read More Sage Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 4/25/2024Confirmed)------- 2/14/2024Q4 2023($1.28)($0.55)+$0.73($0.55)$60.15 million$77.97 million 11/7/2023Q3 2023($2.64)($2.81)($0.17)($2.25)$9.02 million$2.72 million8/7/2023Q2 2023($2.55)($2.68)($0.13)($2.68)$2.94 million$2.47 million 5/2/2023Q1 2023($2.50)($2.46)+$0.04($2.46)$2.28 million$3.30 million 2/16/2023Q4 2022($2.37)($2.47)($0.10)($2.47)$1.94 million$2.87 million 11/8/2022Q3 2022($2.16)($2.31)($0.15)($2.31)$1.68 million$1.74 million Get the Latest News and Ratings for SAGE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022($2.16)($2.13)+$0.03($2.13)$1.77 million$1.50 million 5/3/2022Q1 2022($2.09)($2.07)+$0.02($2.07)$3.23 million$1.58 million 2/24/2022Q4 2021($2.16)($2.12)+$0.04($2.12)$1.77 million$1.65 million 11/2/2021Q3 2021($1.84)($2.21)($0.37)($2.21)$2.00 million$1.44 million 8/3/2021Q2 2021($1.69)($1.83)($0.14)($1.83)$2.01 million$1.60 million 5/4/2021Q1 2021($1.98)($1.64)+$0.34($1.64)$2.03 million$1.58 million Sage Therapeutics Earnings - Frequently Asked Questions When is Sage Therapeutics's earnings date? Sage Therapeutics has confirmed that its next quarterly earnings data will be published on Thursday, April 25th, 2024. Learn more on SAGE's earnings history. Did Sage Therapeutics beat their earnings estimates last quarter? In the previous quarter, Sage Therapeutics (NASDAQ:SAGE) reported ($0.55) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.28) by $0.73. Learn more on analysts' earnings estimate vs. SAGE's actual earnings. How can I listen to Sage Therapeutics's earnings conference call? The conference call for Sage Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Sage Therapeutics's conference call transcript? The conference call transcript for Sage Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Sage Therapeutics generate each year? Sage Therapeutics (NASDAQ:SAGE) has a recorded annual revenue of $86.46 million. How much profit does Sage Therapeutics generate each year? Sage Therapeutics (NASDAQ:SAGE) has a recorded net income of -$541.49 million. SAGE has generated -$9.06 earnings per share over the last four quarters. What is Sage Therapeutics's EPS forecast for next year? Sage Therapeutics's earnings are expected to grow from ($6.30) per share to ($4.53) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Innoviva Earnings Zentalis Pharmaceuticals Earnings Cassava Sciences Earnings Arcutis Biotherapeutics Earnings ARS Pharmaceuticals Earnings 89bio Earnings Liquidia Earnings OPKO Health Earnings MacroGenics Earnings Belite Bio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Taiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later? This page (NASDAQ:SAGE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
